SCHEMBL14211685

SCHEMBL14211685

OCCOCCOc1ccc(Br)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 8/20 0.40
MAPT P10636 1/20 0.40
SNCA P37840 1/20 0.40
KDM4E B2RXH2 2/20 0.39
LSS P48449 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PI4KA P42356 1/20 0.36
PIK3CG P48736 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
GABRA5 P31644 1/20 0.35
MAPK1 P28482 2/20 0.35
ALDH1A1 P00352 2/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20120474 1.00 APP (0.40) APPMAPTSNCAKDM4ELSS
SCHEMBL23720530 1.00 APP (0.40) APPMAPTSNCAKDM4ELSS
SCHEMBL23720528 0.95 LSS (0.41) APPMAPTSNCAKDM4ELSS
SCHEMBL23720518 0.95 LSS (0.41) APPMAPTSNCAKDM4ELSS
SCHEMBL23720314 0.95 LSS (0.41) APPMAPTSNCAKDM4ELSS
SCHEMBL23720320 0.90 APP (0.38) APPMAPTSNCAKDM4ELSS
SCHEMBL1284075 0.89 KDM4E (0.42) APPMAPTKDM4ELSSKMT2A
SCHEMBL23720524 0.89 LSS (0.39) APPMAPTSNCAKDM4ELSS
SCHEMBL23720493 0.89 LSS (0.39) APPMAPTSNCAKDM4ELSS
SCHEMBL23720315 0.89 LSS (0.39) APPMAPTSNCAKDM4ELSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180021451-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE LIGACHEM BIOSCIENCES INC. (KR) 2018-01-25 US disclosed
US-9669107-B2 Antibody-active agent conjugates and methods of use LEGOCHEM BIOSCIENCES, INC. (KR) 2017-06-06 US disclosed
US-9669107-B2 Antibody-active agent conjugates and methods of use LEGOCHEM BIOSCIENCES, INC. (KR) 2017-06-06 US disclosed
US-20160213786-A1 PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE LEGOCHEM BIOSCIENCES, INC. (KR) 2016-07-28 US disclosed
US-20160213786-A1 PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE LEGOCHEM BIOSCIENCES, INC. (KR) 2016-07-28 US disclosed
US-20150105541-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE LIGACHEM BIOSCIENCES INC. (KR) 2015-04-16 US disclosed
US-20150105541-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE LIGACHEM BIOSCIENCES INC. (KR) 2015-04-16 US disclosed
US-20140187756-A1 Methods of preparing antibody-active agent conjugates LEGOCHEM BIOSCIENCES, INC. (KR) 2014-07-03 US disclosed
US-20140187756-A1 Methods of preparing antibody-active agent conjugates LEGOCHEM BIOSCIENCES, INC. (KR) 2014-07-03 US disclosed
US-20140161829-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE LEGOCHEM BIOSCIENCES, INC. (KR) 2014-06-12 US disclosed
US-20140161829-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE LEGOCHEM BIOSCIENCES, INC. (KR) 2014-06-12 US disclosed
US-20120308584-A1 PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME LEGOCHEM BIOSCIENCES, INC. (KR) 2012-12-06 US disclosed
US-20120308584-A1 PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME LEGOCHEM BIOSCIENCES, INC. (KR) 2012-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160213786-A1 PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE FNTA, FCGRT, GGT1 APP 1771/4885MAPT 2332/4885SNCA 3950/4885
US-20150105541-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE FCGRT, CD47, FNTA APP 2374/4885MAPT 2711/4885SNCA 4358/4885
US-20140161829-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE FNTA, FCGRT, CD47 APP 2372/4885MAPT 2687/4885SNCA 4359/4885
US-20180021451-A1 ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE FCGRT, CD47, FNTA APP 2374/4885MAPT 2711/4885SNCA 4358/4885
US-20140187756-A1 Methods of preparing antibody-active agent conjugates FNTA, GGT1, ICMT APP 3071/4885MAPT 3058/4885SNCA 3770/4885
US-20120308584-A1 PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME FNTA, DNPEP, RCE1 APP 916/4885MAPT 2758/4885SNCA 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.